Research by Memorial Sloan Kettering Cancer Centre has linked the use of Omomyc as a kill switch to applications such as engineered T cells. The article Genetic “Kill Switch” Could Make Cell Therapies Safer by Julie Grisham, September 18, 2014 discusses research into Omomyc which demonstrates that normal differentiated cells don't care if you turn Myc off but malignant brain tumors for instance, are Myc dependent and die.
So what kind of cell therapies could benefit from a kill switch? It appears that MSK believed that engineered T cells, chimeric antigen receptors or CAR-T, could benefit. That was 2014 so what happened next? I don't really know but in November 2013 Dr Michel Sadelain, Director of MSK's Center for Cell Engineering along with others founded a new biotechnology company called Juno Therapeutics.
Could Kite Pharma or Novartis be interested in a Myc inhibitor program for similar reasons? I don't really know but it would appear that real champions for iMYC have emerged from the world of Big Pharma.
PYC Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)